Abstract
Gene therapy is a promising technology for the treatment of several acquired and inherited diseases. However, for gene therapy to be a commercial and clinical success, scalable cell culture processes must be in place to produce the required amount of viral vectors to meet market demand. Each type of vector has its own distinct characteristics and consequently its own challenges for production. This article reviews the current technology that has been developed for the efficient, large-scale manufacture of retrovirus, lentivirus, adenovirus, adeno-associated virus and herpes simplex virus vectors.
Similar content being viewed by others
References
Al-Rubeai M., Emery A.N., Chalder S. and Jan D.C. (1992). Specific monoclonal antibody productivity and the cell cycle-comparisons of batchcontinuous and perfusion cultures. Cytotechnology 9: 85–97
Al-Rubeai M., Rookes S. and Emery A. N. (1990). Studies of cell proliferation and monoclonal antibody synthesis and secretion in alginate-entrapped hybridoma cells. In: de Bont, J.A.M., Visser, J., Mattiasson, B., and Tramper, J. (eds) Physiology of Immobilized cells. 10-12-1989, pp 181–188. Elsevier Science Publishers Cells, AmsterdamThe Netherlands
Beer C., Buhr P., Hahn H., Laubner D. and Wirth M. (2003a). Gene expression analysis of murine cells producing amphotropic mouse leukaemia virus at a cultivation temperature of 32 and 37 °C. J. Gen. Virol. 84: 1677–1686
Beer C., Meyer A., Muller K. and Wirth M. (2003b). The temperature stability of mouse retroviruses depends on the cholesterol levels of viral lipid shell and cellular plasma membrane. Virology 308: 137–146
Benihoud K., Yeh P. and Perricaudet M. (1999). Adenovirus vectors for gene delivery. Curr. Opin. Biotechnol. 10: 440–447
Blouin V., Brument N., Toublanc E., Raimbaud I., Moullier P. and Salvetti A. ((2004)). Improving rAAV production and purification: towards the definition of a scaleable process. J Gene Med. 6(1): s223–s228
Braas G., Searle P.F., Slater N.K.H. and Lydiatt A. (1996). Stratagies for the isolation and purification of retroviral vectors for human gene therapy. Bioseparation 6: 211–228
Breyer B., Jiang W., Cheng H., Zhou L., Paul R., Feng T. and He T.C. (2001). Adenoviral vector-mediated gene transfer for human gene therapy. Curr. Gene Ther. 1: 149–162
Brooks A.I., Stein C.S., Hughes S.M., Heth J., Mccray P.M., Sauter S.L., Johnston J.C., Cory-Slechta D.A., Federoff H.J. and Davidson B.L. (2002). Functional correction of established central nervous system deficits in an animal model of lysosomal storage disease with feline immunodeficiency virus-based vectors. Proc. Natl. Acad. Sci. USA 99: 6216–6221
Carroll R., Lin J.T., Dacquel E.J., Mosca J.D., Burke D.S. and St Louis D.C. (1994). A human immunodeficiency virus type 1 (HIV-1)-based retroviral vector system utilizing stable HIV-1 packaging cell lines. J. Virol. 68: 6047–6051
Chuah M.K., Collen D. and Vanden Driessche T. (2003). Biosafety of adenoviral vectors. Curr. Gene Ther. 3: 527–543
Clark K.R. (2002). Recent Advances in Recombinant Adeno-Associated Virus Vector Production. Kidney Int. 61: 9–15
Coleman J.E., Huentelman M.J., Kasparov S., Metcalfe B.L., Paton J.F., Katovich M.J., Semple-Rowland S.L. and Raizada M.K. (2003). Efficient large-scale production and concentration of HIV-1-based lentiviral vectors for use in vivo. Physiol. Genom. 12: 221–228
Collaco R.F., Cao X. and Trempe J.P. (1999). A helper virus-free packaging system for recombinant adeno-associated virus vectors. Gene 238: 397–405
Coroadinha A.S., Schucht R., Gama-Norton L., Wirth D., Hauser H. and Carrondo M.J.T. 2005. The use of recombinase Cassette Exchange in retroviral Vector Producer Cell Lines: predictability and efficiency in transgene replacement. J. Biotechnol.Submitted.
Cortin V., Thibault J., Jacob D. and Garnier A. (2004). High-titer adenovirus vector production in 293S cell perfusion culture. Biotechnol. Prog. 20: 858–863
Côté J., Garnier A., Massie B. and Kamen A. (1998). Serum-free Production of Recombinant Proteins and Adenoviral Vectors by 293SF-3F6 Cells. Biotechnol. Bioeng. 59: 567–575
Cruz P.E., Almeida J.S., Murphy P.N., Moreira J.L. and Carrondo M.J. (2000). Modeling retrovirus production for gene therapy. 1. Determination of optimal bioreaction mode and harvest strategy. Biotechnol. Prog. 16: 213–221
Cruz P.E., Carmo M., Coroadinha A.S., Bengala A., Goncalves D., Teixeira M., Merten O.-W., Gény-Fiamma C. and Carrondo M.J.T. (2005). Retroviral vector stability: inactivation kinetics and membrane properties. In: Godia, F. and Fussenegger, M. (eds) Animal Cell Technology meets Genomics, pp 303–308. Springer, Dordrecht/NL
Curran M.A., Kaiser S.M., Achacoso P.L. and Nolan G.P. (2000). Efficient transduction of nondividing cells by optimized feline immunodeficiency virus vectors. Mol. Ther. 1: 31–38
Davis J.L., Witt R.M., Gross P.R., Hokanson C.A., Jungles S., Cohen L.K., Danos O. and Spratt S.K. (1997). Retroviral particles produced from a stable human-derived packaging cell line transduce target cells with very high efficiencies. Hum. Gene Ther. 8: 1459–1467
Fallaux F.J., Kranenburg O., Cramer S.J., Houweling A., Van Ormondt H., Hoeben R.C. and Van Der Eb A.J. (1996). Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum. Gene Ther. 7(2): 215–222
Fallaux F.J., Bout A., Van Der Velde I., Van Den Wollenberg D.J., Hehir K.M., Keegan J., Auger C., Cramer S.J., Van Ormondt H., Van Der Eb A.J., Valerio D. and Hoeben R.C. (1998). New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum. Gene Ther. 9(13): 1909–1917
Farson D., Harding T.C., Tao L., Liu J., Powell S., Vimal V., Yendluri S., Koprivnikar K., Ho K., Twitty C., Husak P., Lin A., Snyder R.O. and Donahue B.A. (2004). Development and characterization of a cell line for large-scaleserum-free production of recombinant adeno-associated viral vectors. J. Gene Med. 6(12): 1369–1381
Fassnacht D., Rössing S., Singh R.P., Al Rubeai M. and Pörtner R. (1999). Influence of bcl-2 on antibody productivity in high cell density perfusion cultures of hybridoma. Cytotechnology 30: 95–105
Forestell S.P., Bohnlein E. and Rigg R.J. (1995). Retroviral end-point titer is not predictive of gene transfer efficiency: implications for vector production. Gene Ther. 2: 723–730
Forestell S.P., Dando J.S., Chen J., de Vries P., Bohnlein E. and Rigg R.J. (1997). Novel retroviral packaging cell lines: complementary tropisms and improved vector production for efficient gene transfer. Gene Ther. 4: 600–610
Friedmann T. 1997. Overcoming the obstacles to gene therapy. Scientific American, 80–85.
Gao G.P., Yang Y. and Wilson J.M. (1996). Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J. Virol. 70: 8934–8943
Gao G.P., Lu F., Sanmiguel J.C., Tran P.T., Abbas Z., Lynd K.S., Marsh J., Spinner N.B. and Wilson J.M. (2002). Rep/Cap gene amplification and high-yield production of AAV in an A549 cell line expressing Rep/Cap. Mol. Ther. 5: 644–649
Gao X. and Huang L. (1995). Cationic liposome-mediated gene transfer. Gene Ther. 2: 710–722
Garnier A., Cortin V., Thibault J. and Jacob D. (2002). Production of Recombinant Adenovirus by 293 Cells Cultures in Perfusion. Cell Culture Engineering VIII, Snowmass
Garnier A., Cote J., Nadeau I., Kamen A. and Massie B. (1994). Scale-up of the adenovirus expression system for the production of recombinant protein in human 293S cells. Cytotechnology 15: 145–155
Gény-Fiamma C., Millot L., Rocca C., Danos O. and Merten O.W. (2004). Optimization of the production of retroviraol vectors: influences of the sugar source. In: Yagasaki, K., Miura, Y., Hatori, M., and Nomura, Y. (eds) Animal Cell Technology: Basic & Applied Aspects, pp 89–97. Kluwer Academic Publishers, Netherlands
Geraerts M., Michiels M., Baekelandt V., Debyser Z. and Gijsbers R. 2005. Upscaling of lentiviral vector production by tangential flow filtration. J. Gene Med. Published online May 20, 2005. http://dx.doi.org/10.1002/jgm.778.
Gerin P.A., Gilligan M.G., Searle P.F. and Al-Rubeai M. (1999a). Improved titers of retroviral vectors from the human FLYRD18 packaging cell line in serum- and protein-free medium. Hum. Gene Ther. 10: 1965–1974
Gerin P.A., Searle P.F. and Al-Rubeai M. (1999b). Production of retroviral vectors for gene therapy with the human packaging cell line FLYRD18. Biotechnol. Prog. 15: 941–948
Ghivizzani S.C., Lechman E.R., Tio C., Mule K.M., Chada S., McCormack J.E., Evans C.H. and Robbins P.D. (1997). Direct retrovirus-mediated gene transfer to the synovium of the rabbit knee: implications for arthritis gene therapy. Gene Ther. 4: 977–982
Graham F.L., Smiley J., Russell W.C. and Nairn R. (1977). Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36: 59–74
Griffiths J.B. (1988). Overview of cell culture systems and their Scale-up. In: Spier, R.E. and Griffiths, J.B. (eds) Animal Cell Biotechnology, vol. 3, pp 179–220. Academic Press Limited, London
Grimm D., Kern A., Rittner K. and Kleinschmidt J.A. (1998). Novel tools for production and purification of recombinant adenoassociated virus vectors. Hum. Gene Ther. 9: 2745–2760
Grimm D. (1999). Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2. Gene Ther. 6: 1322–1330
Haselhorst D., Kaye J.F. and Lever A.M. (1998). Development of cell lines stably expressing human immunodeficiency virus type 1 proteins for studies in encapsidation and gene transfer. J. Gen. Virol. 79(Pt 2): 231–237
He T.C., Zhou S., da Costa L.T., Yu J., Kinzler K.W. and Vogelstein B. (1998). A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. USA 95: 2509–2514
Kost T.A., Klein J.L. and Condreay J.P. 2000. Application of recombinant baculoviruses in biopharmaceutical research. In: Al-Rubeai M. (ed.), Cell Engineering, Vol. 2: Transient Expression. Kluwer Academic Publications, pp.1–28.
Ikeda Y., Takeuchi Y., Martin F., Cosset F.L., Mitrophanous K. and Collins M. (2003). Continuous high-titer HIV-1 vector production. Nat. Biotechnol. 21: 569–572
Imler J.L., Chartier C., Dreyer D., Dieterle A., Sainte-Marie M., Faure T., Pavirani A. and Mehtali M. (1996). Novel complementation cell lines derived from human lung carcinoma A549 cells support the growth of E1-deleted adenovirus vectors. Gene Ther. 3: 75–84
Imren S., Payen E., Westerman K.A., Pawliuk R., Fabry M.E., Eaves C.J., Cavilla B., Wadsworth L.D., Beuzard Y., Bouhassira E.E., Russell R., London I.M., Nagel R.L., Leboulch P. and Humphries R.K. (2002). Permanent and panerythroid correction of murine beta thalassemia by multiple lentiviral integration in hematopoietic stem cells. Proc. Natl. Acad Sci USA 99: 14380–14385
Iyer P., Ostrove J.M. and Vacante D. (1999). Comparison of manufacturing techniques for adenovirus production. Cytotechnology 30: 169–172
Jardon M. and Garnier A. (2003). pH, pCO2temperature effect on r-adenovirus production. Biotechnol. Prog. 19: 202–208
Jenny C., Toublanc E., Danos O. and Merten O.-W. 2005. Evaluation of a serum-free medium for the production of rAAV-2 using HeLa derived producer cells. Cytotechnology.In press.
Johnson P.A., Yoshida K., Gage F.H. and Friedmann T. (1992). Effects of gene transfer into cultured CNS neurons with a replication-defective herpes simplex virus type 1 vector. Brain Res Mol. Brain Res. 12: 95–102
Johnston J.C., Gasmi M., Lim L.E., Elder J.H., Yee J.K., Jolly D.J., Campbell K.P., Davidson B.L. and Sauter S.L. (1999). Minimum requirements for efficient transduction of dividing and nondividing cells by feline immunodeficiency virus vectors. J. Virol. 73: 4991–5000
Kafri T., van Praag H., Ouyang L., Gage F.H. and Verma I.M. (1999). A packaging cell line for lentivirus vectors. J. Virol. 73: 576–584
Kamen A. and Henry O. (2004). Development and optimization of an adenovirus production process. J. Gene Med. 6: S184–S192
Kang S.-H., Lee G.M. and Kim B.-G. (2000). Justification of continuous packed-bed reactor for retroviral vector production from amphotopic ψ CRIP murine producer cell. Cytotechnology 34: 151–158
Kaptein L.C., Greijer A.E., Valerio D. and van Beusechem V.W. (1997). Optimized conditions for the production of recombinant amphotropic retroviral vector preparations. Gene Ther. 4: 172–176
Karavodin L.M., Robbins J., Chong K., Hsu D., Ibanez C., Mento S., Jolly D. and Fong T.C. (1998). Generation of a systemic antitumor response with regional intratumoral injections of interferon gamma retroviral vector. Hum. Gene Ther. 9: 2231–2241
Kioukia N., Nienow A.W., Al-Rubeai M. and Emery A.N. (1996). Influence of agitation and sparging on the growth rate and infection of insect cells in bioreactors and comparison with hybridoma culture. Biotechnol. Prog. 12: 779–785
Kim S.H., Kim S. and Robbins P.D. (2000). Retroviral vectors. Adv. Virus Res. 55: 545–563
Kotani H., Zhang S., Chiang Y.L., Otto E., Weaver L., Blaese R.M., Anderson W.F., McGarrity G.J. and Newton P.B. (1994). Improved methods of retroviral vector transduction and production for gene therapy. Hum. Gene Ther. 5: 19–28
Krisky D.M., Wolfe D., Goins W.F., Marconi P.C., Ramakrishnan R., Mata M., Rouse R.J., Fink D.J. and Glorioso J.C. (1998). Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons. Gene Ther. 5: 1593–1603
Lai C.M., Lai Y.K.Y. and Rakoczy P.E. (2002). Adenovirus and adeno-associated virus vectors. DNA Cell Biol. 21: 895–913
Le Doux J.M., Davis H.E., Morgan J.R. and Yarmush M.L. (1999). Kinetics of retrovirus production and decay. Biotechnol. Bioeng. 63: 654–662
Lee S.G., Kim S., Robbins P.D. and Kim B.G. (1996). Optimization of environmental factors for the production and handling of recombinant retrovirus. Appl. Microbiol. Biotechnol. 45: 477–483
Lee Y.Y., Yap M.G., Hu W.S. and Wong K.T. (2003). Low-glutamine fed-batch cultures of 293-HEK serum-free suspension cells for adenovirus production. Biotechnol. Prog. 19: 501–509
Lever A.M.L., Strappe P.M. and Zhao J. (2004). Lentiviral Vectors. J. Biomed. Sci. 11: 439–449
Lochmuller H., Jani A., Huard J., Prescott S., Simoneau M., Massie B., Karpati G. and Acsadi G. (1994). Emergence of early region 1-containing replication-competent adenovirus in stocks of replication-defective adenovirus recombinants (delta E1 + delta E3) during multiple passages in 293 cells. Hum. Gene Ther. 5: 1485–1491
Loewen N., Leske D.A., Chen Y., Teo W.L., Saenz D.T., Peretz M., Holmes J.M. and Poeschla E.M. (2003). Comparison of wild-type and class I integrase mutant-FIV vectors in retina demonstrates sustained expression of integrated transgenes in retinal pigment epithelium. J. Gene Med. 5: 1009–1017
Looby D. and Griffiths B. (1990). Immobilisation of animal cells in porous carrier culture. Trends Biotechnol. 8: 204–209
Lyddiat A. and O’Sullivan D.A. (1998). Biochemical recovery and purification of gene therapy vectors. Curr. Opin. Biotechnol. 9: 177–185
Mannix C. and Jarman R.F. 2000. A guide to successful scale-up of the baculovirus expression system. In: Al-Rubeai M.(eds) Cell Engineering, Vol. 2: Transient Expression. Kluwer Academic Publications, pp. 43–55.
Matsushita T., Elliger S., Elliger C., Podsakoff G., Villarreal L., Kurtzman G.J., Iwaki Y. and Colosi P. (1998). Adeno- associated virus vectors can be efficiently produced without helper virus. Gene Ther. 5: 938–945
McTaggart S. 2000. Retroviral Vector Production for Gene Therapy Applications. Ph. D. Thesis, University of Birmingham.
McTaggart S. and Al-Rubeai M. (2000). Effects of culture parameters on the production of retroviral vectors by a human packaging cell line. Biotechnol. Prog. 16: 859–865
McTaggart S. and Al-Rubeai M. (2001). Relationship between cell proliferation, cell-cycle phaseand retroviral vector production in FLYRD18 human packaging cells. Biotechnol. Bioeng. 76: 52–60
McTaggart S. and Al-Rubeai M. (2002). Retroviral vectors for human gene delivery. Biotechnol. Adv. 20: 1–31
Meghrous J., Aucoin M.G., Jacob D., Chahal P.S., Arcand N. and Kamen A.A. (2005). Production of recombinant adeno-associated viral vectors using a baculovirus/insect cell suspension culture system: from shake flasks to a 20-L bioreactor. Biotechnol. Prog. 21: 154–160
Mellerick D.M. and Fraser N. (1987). Physical state of the latent herpes simplex virus genome in a mouse model system: evidence suggesting an episomal state. Virology 158: 265–275
Merten O.-W. (2004). State-of-the-art of the production of retroviral vectors. J. Gene Med. 6: S105–S124
Merten O.-W., Cornet V., Petres S., Couvé E. and Heard J.M. (1996). Large scale production of retrovirus vectors (abstract). Cytotechnology 21: 8
Merten O.-W., Cruz P.E., Rochette C., Gény-Fiamma C., Bouquet C., Goncalves D., Danos O. and Carrondo M.J.T. (2001a). Comparison of different bioreactor systems for the production of high titer retroviral vectors. Biotechnol. Prog. 17: 326–335
Merten O.-W., Gény-Fiamma C. and Douar A.M. (2005). Current issues in adeno-associated viral vectors production. Gene Ther. 12: S51–S61
Merten O.-W., Landric L. and Danos O. (2001b). Influence of the metabolic status of packaging cells on retroviral vector production. In: Merten, O.-W., Mattanovich, D., Lang, C., Larsson, G., Neubauer, P., Porro, D., Postma, P., Teixeira de Mattos, J., and Cole, J.A. (eds) Recombinant Protein Production with Prokaryotic and Eukayotic Cells A Comparative View on Host Physiology, pp 303–318. Kluwer Academic Publishers, Netherlands
Michael S.I. and Curiel D.T. (1994). Strategies to achieve targeted gene delivery via the receptor-mediated endocytosis pathway. Gene Ther. 1: 223–232
Mitrophanous K., Yoon S., Rohll J., Patil D., Wilkes F., Kim V., Kingsman S., Kingsman A. and Mazarakis N. (1999). Stable gene transfer to the nervous system using a non-primate lentiviral vector. Gene Ther. 6: 1808–1818
Nadeau I., Garnier A., Cote J., Massie B., Chavarie C. and Kamen A. (1996). Improvement of recombinant protein production with the human adenovirus/293S expression system using fed-batch strategies. Biotechnol. Bioeng. 51: 613–623
Nadeau I., Gilbert P.A., Jacob D., Perrier M. and Kamen A. (2002a). Low-protein medium affects the 293SF central metabolism during growth and infection with adenovirus. Biotechnol. Bioeng. 77: 91–104
Nadeau I., Jacob D., Perrier M. and Kamen A. (2000). 293SF metabolic flux analysis during cell growth and infection with an adenoviral vector. Biotechnol. Prog. 16: 872–884
Nadeau I. and Kamen A. (2003). Production of adenovirus vector for gene therapy. Biotechnol. Adv. 20: 475–489
Nadeau I., Seanez G. and Wu F. 2001. Adenovirus production in 293 cells: a comparative study between a suspension cell and an adherent cell process. The 17th ESACT Meeting, Tylosand, Sweden, June 10–14.
Nadeau I., Seanez G. and Wu F. 2002b. Optimization of a 293 suspension process for adenovirus production. Cell Culture Engineering VIII, Snowmass, Colorado, April 1–6.
Navarro J., Oudrhiri N., Fabrega S. and Lehn P. (1998). Gene delivery systems: bridging the gap between recombinant viruses and artificial vectors. Adv. Drug Deliv. Rev. 30: 5–11
Nemunaitis J., Fong T., Burrows F., Bruce J., Peters G., Ognoskie N., Meyer W., Wynne D., Kerr R., Pippen J., Oldham F. and Ando D. (1999). Phase I trial of interferon gamma retroviral vector administered intratumorally with multiple courses in patients with metastatic melanoma. Hum. Gene Ther. 10: 1289–1298
Ni Y., Sun S., Oparaocha I., Humeau L., Davis B., Cohen R., Binder G., Chang Y.N., Slepushkin V. and Dropulic B. (2005). Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector. J. Gene Med. 7(6): 818–834
Olsen J.C. (1998). Gene transfer vectors derived from equine infectious anemia virus. Gene Ther. 5: 1481–1487
Olsen J.C. and Sechelski J. (1995). Use of sodium butyrate to enhance production of retroviral vectors expressing CFTR cDNA. Hum. Gene Ther. 6: 1195–1202
Ozuer A., Wechuck J.B., Goins W.F., Wolfe D., Glorioso J.C. and Ataai M.M. (2002). Effect of genetic background and culture conditions on the production of herpesvirus-based gene therapy vectors. Biotechnol. Bioeng. 77: 685–692
Pages J.C., Loux N., Farge D., Briand P. and Weber A. (1995). Activation of Moloney murine leukemia virus LTR enhances the titer of recombinant retrovirus in psi CRIP packaging cells. Gene Ther. 2: 547–551
Palu G., Bonaguro R. and Marcello A. (1999). In pursuit of new developments for gene therapy of human diseases. J. Biotechnol. 68: 1–13
Pan D. and Whitley C.B. (1999). Closed hollow-fiber bioreactor: a new approach to retroviral vector production. J. Gene Med. 1: 433–440
Parasrampuria D.A. and Hunt C.A. 1998. Therapeutic delivery issues in gene therapy, Part 1: Vectors. BioPharm, 38–45.
Parks R.J., Chen L., Anton M., Sankar U., Rudnicki M.A. and Graham F.L. (1996). A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc. Natl. Acad. Sci. USA 93: 13565–13570
Pear W.S., Nolan G.P., Scott M.L. and Baltimore D. (1993). Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. USA 90: 8392–8396
Pensiero M.N., Wysocki C.A., Nader K. and Kikuchi G.H. (1996). Development of amphotropic murine retrovirus vectors resistant to inactivation by human serum. Hum. Gene Ther. 7: 1095–1101
Peshwa M.V., Kyung Y.-S., McClure D.B. and Hu W.-S. (1993). Cultivation of mammalian cells as aggregates in bioreactors: effect of calcium concentration on spatial distribution of viability. Biotechnol. Bioeng. 41: 179–187
Pizzato M., Merten O.W., Blair E.D. and Takeuchi Y. (2001). Development of a suspension packaging cell line for production of high titreserum-resistant murine leukemia virus vectors. Gene Ther. 8: 737–745
Rigg R.J., Chen J., Dando J.S., Forestell S.P., Plavec I. and Bohnlein E. (1996). A novel human amphotropic packaging cell line: high titercomplement resistanceand improved safety. Virology 218: 290–295
Robbins P.D., Hideaki T. and Ghivizzani S.C. (1998). Viral vectors for gene therapy. Trends Biotechnol. 16: 35–40
Sadaie M.R., Zamani M., Whang S., Sistron N. and Arya S.K. (1998). Towards developing HIV-2 lentivirus-based retroviral vectors for gene therapy: dual gene expression in the context of HIV-2 LTR and Tat. J. Med. Virol 54: 118–128
Sallberg M., Hughes J., Javadian A., Ronlov G., Hultgren C., Townsend K., Anderson C.G., O’Dea J., Alfonso J., Eason R., Murthy K.K., Jolly D.J., Chang S.M., Mento S.J., Milich D. and Lee W.T. (1998). Genetic immunization of chimpanzees chronically infected with the hepatitis B virus using a recombinant retroviral vector encoding the hepatitis B virus core antigen. Hum. Gene Ther. 9: 1719–1729
Salvetti A., Oreve S., Chadeuf G., Favre D., Cherel Y., Champion-Arnaud P., David-Ameline J. and Moullier P. (1998). Factors influencing recombinant adeno-associated virus production. Hum. Gene Ther. 9: 695–706
Schiedner G., Hertel S. and Kochanek S. (2000). Efficient transformation of primary human amniocytes by E1 functions of Ad5: generation of new cell lines for adenoviral vector production. Hum. Gene Ther. 11: 2105–2116
Schnell T., Foley P., Wirth M., Munch J. and Uberla K. (2000). Development of a self-inactivating, minimal lentivirus vector based on simian immunodeficiency virus. Hum. Gene Ther. 11: 439–447
Schonely K., Afable C., Slepushkin V., Lu X., Andre K., Boehmer J., Bengtson K., Doud M., Cohen R., Berlinger D., Slepushkina T., Chen Z., Li Y., Binder D., Davis B., Humeau L. and Dropulic B. (2003). QC release testing of an HIV-1 based lentiviral vector lot and transduced cellular product. Bioproc. J. 2: 29–47
Schucht R., Coroadinha A.S., Zanta-Boussif M.A., Carrondo M., Hauser H. and Wirth D. 2005. A new generation of retroviral producer cells: predictable and stable virus production by Flp mediated site-specific integration of retroviral vectors. Mol. Thera. Submitted.
Sena-Esteves M., Tebbets J.C., Steffens S., Crombleholme T. and Flake A.W. (2004). Optimized large-scale production of high titer lentivirus vector pseudotypes. J. Virol. Methods 122: 131–139
Shen B.Q., Clarke M.F. and Palsson D.O. (1996). Kinetics of retroviral production from the amphotrophic ψCRIP murine producer cell line. Cytotechnology 22: 185–195
Shenk T. (1996). Adenoviridae: the viruses and their replication. In: Fields, B.N., Knipe, D.M., Howley, P.M., Chanock, R.M., Melnick, J.L., Monath, T.P., Roizman, B. and Straus, S.E. (eds) Fields Virology, pp 2111–2148. Philadelphia, Lippincott
Sheridan P. L., Bodner M., Lynn A., Phuong T.K., DePolo N.J., O’Dea J., Nguyen K., McCormack J.E., Driver D.A., Townsend K., Ibanez C.E., Sajjadi N.C., Greengard J.S., Moore M.D., Respess J., Chang S.M., Jolly D.J., Sauter S.L., la Vega D.J. and Dubensky T.W. (2000). Generation of retroviral packaging and producer cell lines for large-scale vector production and clinical application: improved safety and high titer. Mol. Ther. 2: 262–275
Starling E.H. (1896). On the absorption of fluids from the convective tissue space. J. Physiol. 19: 312–326
Stitz J., Muhlebach M.D., Blomer U., Scherr M., Selbert M., Wehner P., Steidl S., Schmitt I., Konig R., Schweizer M. and Cichutek K. (2001). A novel lentivirus vector derived from apathogenic simian immunodeficiency virus. Virology 291: 191–197
Takahashi K., Luo T.C., Saishin Y., Saishin Y., Sung J., Hackett S., Brazzell R.K., Kaleko M. and Campochiaro P.A. (2002). Sustained transduction of ocular cells with a bovine immunodeficiency viral vector. Hum. Gene Ther. 13: 1305–1316
Theodossiou I., Thomas O.R.T. and Dunnill R. (1999). Methods for enhancing the recovery of plasmid genes from neutralised cell lysate. Bioproc. Eng. 20: 147–156
Torrent C., Bordet T. and Darlix J.L. (1994). Analytical study of rat retrotransposon VL30 RNA dimerization in vitro and packaging in murine leukemia virus. J. Biol. Med. 240: 434–444
Urabe M., Ding C. and Kotin R.M. (2002). Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum. Gene Ther. 13: 1925–1943
Van Den Driessche T., Vanslembrouck V., Goovaerts I., Zwinnen H., Vanderhaeghen M.L., Collen D. and Chuah M.K. (1999). Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice. Proc. Natl. Acad. Sci. USA 96: 10379–10384
Vos J.-M. H. 1995. Viruses in Human Gene Therapy. Chapman and Hall.
Wang G., Davidson B.L., Melchert P., Slepushkin V.A., van Es H.H., Bodner M., Jolly D.J. and McCray P.B. (1998). Influence of cell polarity on retrovirus-mediated gene transfer to differentiated human airway epithelia. J. Virol. 72: 9818–9826
Warnock J.N. and Al-Rubeai M. 2004. Influence of serum concentration on cell growth and retrovirus production and decay kinetics. In: Yagasaki K., Miura Y., Hatori M. and Nomura Y. (eds), Animal Cell Technology: Basic & Applied Aspects. Kluwer Academic Publishers.
Warnock J. N. and Al-Rubeai M. (2005). Production of Biologics from Animal Cell Cultures. In: Nedovic, V. and Willaert, R. (eds) Applications of Cell Immobilisation Biotechnology, pp. Springer, Berlin, Heidelberg, New York
Warnock J.N., Price T., Slade A. and Al-Rubeai M. (2004). Use of a Fluidised Bed Bioreactor for the Production of Retroviral Vectors for Gene Therapy Applications. Bioproc. J. 3: 41–45
Wechuck J.B., Ozuer A., Goins W.F., Wolfe D., Oligino T., Glorioso J.C. and Ataai M.M. (2002). Effect of temperature medium composition and cell passage on production of herpes-based viral vectors. Biotechnol. Bioeng. 79: 112–119
Wikström K., Blomberg P. and Islam K.B. (2004). Clinical grade vector production: analysis of yieldstability, and storage of gmp-produced retroviral vectors for gene therapy. Biotechnol. Prog. 20: 1198–1203
Wu N. and Ataai M.M. (2000). Production of viral vectors for gene therapy applications. Curr. Opin. Biotechnol. 11: 205–208
Wu N., Watkins S.C., Schaffer P.A. and DeLuca N.A. (1996). Prolonged gene expression and cell survival after infection by a herpes simplex virus mutant defective in the immediate-early genes encoding ICP4, ICP27, and ICP22. J. Virol. 70: 6358–6369
Wu S.C., Huang G.Y. and Liu J.H. (2002). Production of retrovirus and adenovirus vectors for gene therapy: a comparative study using microcarrier and stationary cell culture. Biotechnol. Prog. 18: 617–622
Xiao X., Li J. and Samulski R.J. (1998). Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J. Virol. 72: 2224–2232
Xie L., Metallo C., Warren J., Pilbrough W., Peltier J., Zhong T., Pikus L., Yancy A., Leung J., Aunins J.G. and Zhou W. (2003). Large-scale propagation of a replication-defective adenovirus vector in stirred-tank bioreactor PER.C6 cell culture under sparging conditions. Biotechnol. Bioeng. 83: 45–52
Xie L., Pilbrough W., Metallo C., Zhong T., Pikus L., Leung J., Aunins J.G. and Zhou W. (2002). Serum-free suspension cultivation of PER.C6(R) cells and recombinant adenovirus production under different pH conditions. Biotechnol. Bioeng. 80: 569–579
Yamaji H. and Fukuda H. (1992). Growth and death behavior of anchorage-independent animal-cells immobilized within porous support matrices. App. Micro. Biotechnol. 37: 244–251
Yuk I.H.Y., Olsen M.M., Geyer S. and Forestell S.P. (2004). Perfusion cultures of human tumor cells: A scalable production platform for oncolytic adenoviral vectors. Biotechnol. Bioeng. 86: 637–642
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Warnock, J.N., Merten, OW. & Al-Rubeai, M. Cell Culture Processes for the Production of Viral Vectors for Gene Therapy Purposes. Cytotechnology 50, 141–162 (2006). https://doi.org/10.1007/s10616-005-5507-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10616-005-5507-z